|
Sarcoma, Myeloid
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our current series, combined with a literature review, identifies a compelling series of 31 (94%) of 33 cases of myeloid sarcoma with CBFB-MYH11 fusion showing a marked predilection for abdominal sites.
|
31671434 |
2020 |
|
Hepatitis B
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CBFβ expression was lower in HBV patients than in healthy persons, and the addition of serum from HBV patients inhibited CBFβ expression in HepG2 cells.
|
29523836 |
2019 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These data establish CBFβ as a mediator of CDK11<sup>p110</sup> dependent oncogenesis and suggest that targeting the CDK11- CBFβ pathway may be a promising therapeutic strategy for osteosarcoma treatment.
|
31610798 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
We found that circ-CBFB knockdown significantly suppressed CLL cell proliferation, arrested cell cycle progression, and induced cellular apoptosis.
|
29902450 |
2018 |
|
Preleukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this review, we will discuss the current understanding of inv(16) preleukemia development, and the function of CBFβ-SMMHC related to preleukemia progression and LIC activity.
|
29755956 |
2018 |
|
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study investigates the effects of chemical inhibition of the CBFβ/RUNX protein-protein interaction on ovarian cancer cell lines.
|
29551565 |
2018 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study investigates the effects of chemical inhibition of the CBFβ/RUNX protein-protein interaction on ovarian cancer cell lines.
|
29551565 |
2018 |
|
MYELODYSPLASTIC SYNDROME
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In this review, we will discuss the current understanding of inv(16) preleukemia development, and the function of CBFβ-SMMHC related to preleukemia progression and LIC activity.
|
29755956 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study investigates the effects of chemical inhibition of the CBFβ/RUNX protein-protein interaction on ovarian cancer cell lines.
|
29551565 |
2018 |
|
Hematological Disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
|
28299658 |
2017 |
|
Myeloid Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The co-expression of p<sup>210BCR-ABL</sup> and <i>CBFβ-MYH11</i> fusion genes in myeloid leukemia may be a molecular event occurring not only during the development of CML, but also in AML.
|
29151902 |
2017 |
|
Nephroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We also concomitant monitoring of fusion transcripts (PML RARa, AML1-ETO, MLL-MLL, CBFb-MYH11, or DEK-CAN) in our patients, the AML1-ETO group showing remarkably low levels of WT1 compared with other fusion transcript and the CBFB-MYH11 showing high levels of WT1.
|
28567073 |
2017 |
|
Osteoporosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results show that, besides its osteogenic role, Cbfβ governs osteoblast-adipocyte lineage commitment both cell nonautonomously through enhancing β-catenin signaling and cell autonomously through suppressing adipogenesis gene expression to maintain osteoblast lineage commitment, indicating Cbfβ may be a therapeutic target for osteoporosis.
|
28864530 |
2017 |
|
Childhood Acute Myeloid Leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR)-based detection of abnormal fusion transcripts is an important strategy for the diagnosis and monitoring of patients with acute myeloid leukemia (AML) with t(8;21)(q22;q22); RUNX1-RUNX1T1, inv(16)(p13.1;q22); CBFB-MYH11 or t(15;17)(q22;q12); PML-RARA.
|
28735486 |
2017 |
|
Hematologic Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Mutations in RUNX1 and CBFB have long been recognized as important in hematological malignancies.
|
28299663 |
2017 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We demonstrate that a small molecule inhibitor, designed to interfere with CBFβ binding to RUNX proteins, impairs the growth of human T-ALL cell lines and primary patient samples.
|
28790107 |
2017 |
|
Lobular carcinoma in situ of breast
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The constellation of somatic mutations found in LCIS (n = 34) and ILC (n = 21) were similar, with the most frequently mutated genes being CDH1 (56% and 66%, respectively), PIK3CA (41% and 52%, respectively) and CBFB (12% and 19%, respectively).
|
26643573 |
2016 |
|
Invasive Lobular Breast Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The constellation of somatic mutations found in LCIS (n = 34) and ILC (n = 21) were similar, with the most frequently mutated genes being CDH1 (56% and 66%, respectively), PIK3CA (41% and 52%, respectively) and CBFB (12% and 19%, respectively).
|
26643573 |
2016 |
|
Myeloid leukemia associated with Down Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The most common subgroups were KMT2A rearrangement (29%), normal karyotype (15%), RUNX1-RUNX1T1 (10%), deletions of 5q, 7q and/or 17p (9%), myeloid leukaemia associated with Down syndrome (7%), PML-RARA (7%) and CBFB-MYH11 (5%).
|
27022003 |
2016 |
|
Adenocarcinoma
|
0.010 |
GeneticVariation
|
group |
BEFREE |
We also observe somatic ELF3 (13%) and CBFB (8%) mutations in 24 adenocarcinomas.
|
24390348 |
2014 |
|
Monosomy
|
0.010 |
GeneticVariation
|
group |
BEFREE |
We report a case of acute myeloid leukemia with a balanced t(16;16)(p13;q22) and additional monosomy 13 showing a new CBFB-MYH11 fusion transcript variant.
|
24342433 |
2014 |
|
Immunologic Deficiency Syndromes
|
0.010 |
Biomarker
|
group |
BEFREE |
Vif proteins of human and simian immunodeficiency viruses require cellular CBFβ to degrade APOBEC3 restriction factors.
|
22205746 |
2012 |
|
Mastocytosis, Systemic
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The mutation is also frequently detected in core-binding factor acute myeloid leukemia (CBF AML) defined by the presence of t(8;21)(q22;q22); RUNX1-RUNX1T1 or inv(16)(p13.1;q22)/t(16;16)(p13.1;q22); CBFB-MYH11 chromosomal rearrangements, but whether the mutation is indicative of associated SM is unclear.
|
22145956 |
2012 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
These data collectively suggest that CBFβ is required for malignancy in some human cancers.
|
20607802 |
2010 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Dysregulation of the transcription factors SOX4, CBFB and SMARCC1 correlates with outcome of colorectal cancer.
|
19156145 |
2009 |